Exabis Library
Welcome to the e-CCO Library!
P578: Therapeutic strategies in the approach of paradoxical psoriasis in IBD: experience of a centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P578: Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort series
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P579 Randomised open-label controlled trial of ciprofloxacin/doxycycline/hydroxychloroquine combination compared with standard budesonide in active Crohn’s disease (APRICOT)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P579: Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutation
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P579: Online Education Significantly Improved Gastroenterologists' Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P579: Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P579: Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P579: Risk of CMV reactivation in UC patients with previous history of CMV infection following infliximab or vedolizumab treatments
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P579: Wearable Devices Can Predict Disease Activity in inflammatory bowel disease Patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P580 Irritable bowel syndrome in inflammatory bowel disease after remission: correlation with remission patterns and inflammation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P580: Benchmarking IBD Pharmacy Services to optimise, strengthen and align IBD Expert Pharmacy Practice
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P580: Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P580: Improvement in disease activity is associated with less disability in a prospective study of paediatric transition patients with IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P580: Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P580: Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P580: Vitamin D substitution dose in IBD patients: Higher than recommended?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P581 Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn’s disease: First real-life experiences
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P581: Complementary and alternative therapies for inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P581: Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn's disease: European multicentre study with a propensity-score matched analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P581: Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM